Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Akebia Therapeutics (AKBA) has a market cap of $0.49 billion USD. According to our data, Akebia Therapeutics is ranked No.5985 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.49 B |
19.10%
|
| Dec 31, 2024 | $0.41 B |
53.23%
|
| Dec 29, 2023 | $0.27 B |
114.90%
|
| Dec 30, 2022 | $0.13 B |
-74.47%
|
| Dec 31, 2021 | $0.49 B |
-19.29%
|
| Dec 31, 2020 | $0.61 B |
-55.70%
|
| Dec 31, 2019 | $1.38 B |
14.29%
|
| Dec 31, 2018 | $1.21 B |
-62.81%
|
| Dec 29, 2017 | $3.24 B |
42.84%
|
| Dec 30, 2016 | $2.27 B |
-19.43%
|
| Dec 31, 2015 | $2.82 B |
11.00%
|
| Dec 31, 2014 | $2.54 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 FibroGen
FGEN
|
$29.89 M |
0.000 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
UK
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
 Takeda Pharmaceutical
TAK
|
$45.76 B |
0.002 M
|
Japan
|
| Market Cap | = | AKBA Stock Price | * | AKBA Shares Outstanding |
| = | $1.89 | * | 0.26 B | |
| = | $0.49 B |